Fiche société
Hebei Senlang Biotechnology Inc., Ltd.
Traitements, essais et publications liés.
Traitements6programmes
Essais2liés
Publications0liées
SourceDBlocale
Traitements
6| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| CD19 CAR-TThis is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Non-hodgkin's lymphoma. A total of 100 patients are planned to be enrolled over a period of 3 years. | SEP | Phase 1 | Thérapie cellulaire + Immunomodulation | China | À vérifier |
| CD19+CD22 CAR-TThis is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Non-hodgkin's lymphoma. A total of 100 patients are planned to be enrolled over a period of 3 years. | SEP | Phase 1 | Thérapie cellulaire + Immunomodulation | China | À vérifier |
| CD22 CAR-TThis is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Non-hodgkin's lymphoma. A total of 100 patients are planned to be enrolled over a period of 3 years. | SEP | Phase 1 | Thérapie cellulaire + Immunomodulation | China | À vérifier |
| S1904 CD19 CAR-TTo evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL. | SEP | Phase 2 | Thérapie cellulaire | China | À vérifier |
| CD19 CAR-TThis is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Non-hodgkin's lymphoma. A total of 100 patients are planned to be enrolled over a period of 3 years. | SEP | Phase 1 | Thérapie cellulaire + Immunomodulation | China | À vérifier |
| S1904 CD19 CAR-TTo evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL. | SEP | Phase 2 | Thérapie cellulaire + Immunomodulation | China | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| S1904 CD19 CAR-T | SEP | Phase 2 | NCT07244406 | Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL | RECRUITING |
| CD19 CAR-T | SEP | Phase 1 | NCT04626739 | CAR-T Cells in Treating Patients With Relapsed or Refractory NHL | UNKNOWN |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||